Cipla Ltd — Q4 FY24
Cipla reported Q4 FY24 revenue of INR 6,163 crore, up 10% YoY, with EBITDA margin expanding 95 bps to 21.4%.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
50%Questions answered4Evaded / deflected12Questions auditedContradictedNumbers vs filing
Answered
High priority
Explain trade generic segment restructuring and impact on Q1.
Asked by Saion Mukherjee, Nomura
Management clearly explained the restructuring and acknowledged potential Q1 impact.
Read the exchange
Question
Just can you explain the dynamics in the trade generic segment? You talked about some restructuring on the channel. What exactly is that, and what's the impact you expect in the first quarter there?
Ashish Adukia, CFO
On trade generic, the model change is that we used to have a sole CFA agent, and now that converts into only a marketing agent. So we will have direct connect with the stockists. This requires administrative changes, due to which there can be some hiccups in the first quarter.
Evasive
Medium priority
What is trade generics contribution to One India?
Asked by Saion Mukherjee, Nomura
Management declined to provide the specific contribution, only stating it's similar to prior years.
no number givenrefused to disclose
Read the exchange
Question
What's the total contribution to the One India number from the trade generics?
Ashish Adukia, CFO
The split, we usually don't give that split. It's the same split as both halves grown, trade generic slightly higher than the RX market. So the split is broadly same as has been in the previous years.
Partial answer
High priority
Update on inorganic investments and interest in semi-specialty assets.
Asked by Kunal Randeria, Axis Capital
Management gave directional strategy but no specific numbers or asset names.
no specific amount givenvague on asset types
Read the exchange
Question
A few years back, you had made some forays in semi-specialty products like IV Tramadol, Pulmazole. So while I understand it didn't work out, are you still keeping your options open? And if so, perhaps you would like to tell us which kind of assets you would be interested in and the amount that you would be comfortable investing?
Ashish Adukia, CFO
With India, we are fairly comfortable with the growth available. We can make a large acquisition in India in white spaces. When it comes to U.S., it won't be a large acquisition, focused on products with differentiation, supply constraint or lower competition.
Evasive
Medium priority
What percentage of India manufacturing is in-house vs outsourced?
Asked by Nitesh Dutt, Burman Capital
Management avoided providing a specific percentage, citing variability.
no number givendeflected to seasonality
Read the exchange
Question
What percentage of the manufacturing is currently being done in-house, and what percentage is outsourced? And will you be maintaining the same mix going forward?
Umang Vohra, CEO
We have a larger share of the prescription business manufactured in Cipla facilities than the generic business. It varies quarter by quarter due to seasonality. Difficult to give a picture other than a larger share of prescription business comes from in-house.
Partial answer
Medium priority
Market opportunity for peptide assets filed and manufacturing source.
Asked by Damayanti Kerai, HSBC
Management confirmed CMO but gave only vague market opportunity description.
no specific market size given
Read the exchange
Question
You mentioned in your presentation 12 assets were filed in peptides and complex generics. So just want some more color on the market opportunity for some of these critical assets, and whether these will be manufactured in-house or through CMO?
Ashish Adukia, CFO
Peptides, all of our peptides is manufactured by our third-party partners. On market opportunities, some of them can be large opportunities, like in case of our current portfolio. But there's a long tail as well.
Answered
High priority
Will US growth come from current portfolio or new launches?
Asked by Damayanti Kerai, HSBC
Management clearly stated both current portfolio and new launches will contribute.
Read the exchange
Question
With $900 million base now, you mentioned like you'll sustain growth, but whether for that new launches like your Abraxane, et cetera, should come in, or you believe current portfolio has significant headroom to sustain growth from this $900 million base, even for FY 2025?
Umang Vohra, CEO
We think the current portfolio has opportunity within the set of products, because Albuterol can be slightly higher in share, lanreotide can still increase its share. So there is a fair amount we can build out of the current portfolio, but also from new launches. The step function jumps in growth will come more from new launches.
Partial answer
High priority
Update on Goa plant FDA inspection and Abraxane launch timing.
Asked by Damayanti Kerai, HSBC
Management provided timeline but with caveats, no commitment on launch.
no firm date givendependent on uncertain inspection
Read the exchange
Question
Any update on Goa plant from FDA side, when they would likely come, and do you still expect Abraxane to potentially see launch in this fiscal year?
Umang Vohra, CEO
The timing of Abraxane is gonna depend on the Goa inspection. We think the Goa inspection, from our last inspection, we will be completing roughly about two years in July, August of this time frame. So around that time or beyond it, is probably the time to expect the reinspection.
Answered
Medium priority
Update on biosimilar, CAR-T, mRNA investments.
Asked by Surya Patra, PhillipCapital
Management gave specific updates on each area.
Read the exchange
Question
Earlier, we have already talked about biosimilar alliance and spending towards CAR-T kind of therapies, mRNA. So is there any update on that side, or are we seeing any kind of meaningful progress on those front as a growth driver for our future business?
Umang Vohra, CEO
We are beginning to see to make choices on capital allocation. We are now in the process of setting up an mRNA lab in Germany. Biosimilar asset is now hopefully going to enter phase one soon. On CAR-T, we are evaluating what we can do.
Evasive
High priority
Does EBITDA guidance of 24.5%-25.5% include higher Revlimid sales?
Asked by Amey, JM Financial
Management did not confirm whether Revlimid is included, only restated the guidance.
did not directly answer yes/nodeflected to overall guidance
Read the exchange
Question
Does the guidance include the higher sales of Revlimid in FY 2025 over FY 2024?
Ashish Adukia, CFO
This is an overall EBITDA guidance that we're giving of 24.5%-25.5% across all markets.
Partial answer
Medium priority
Details on Sanofi CNS tie-up: contract structure and profitability.
Asked by Amey, JM Financial
Management described strategic rationale but did not disclose contract structure or profitability.
no specific financial terms given
Read the exchange
Question
On the Sanofi tie-up, which we have done for CNS products. If we can give more color on this tie-up, are these products complementary to our portfolio? And also, what is the contract structure for these kind of products?
Umang Vohra, CEO
These will be very typical to licensing arrangements that we have on other products. There's going to be not much difference in the terms here versus the other. But it adds strategic value to be present in a category where we believe we can complete the offering in the CNS space.
Declined
High priority
Revenue growth expectations for FY25?
Asked by Kunal Dhamesha, Macquarie
Management explicitly stated they do not provide revenue growth guidance.
refused to give guidance
Read the exchange
Question
Have we put out, have I missed something as to what are expectations for in terms of revenue growth for financial point?
Ashish Adukia, CFO
We do not give revenue growth guidance, but certainly for our core markets of India, U.S., as well as South Africa, and then especially India and South Africa, because that's actively tracked and we are guiding towards that.
Answered
Medium priority
Are you factoring incremental competition in Albuterol and Lanreotide?
Asked by Alankar Garude, Kotak Institutional Equities
Management confirmed they are factoring in competition.
Read the exchange
Question
When you talk about increasing share in Albuterol and Lanreotide in FY 25, are you factoring in incremental competition in both these products?
Ashish Adukia, CFO
Yes. Like, whatever new players are likely to come in, we are cognizant of that, and, with that, we are aiming to increase our market share.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Sanofi CNS portfolio sales about INR 150 crore (corrected from 250) | ₹150 cr | ₹6,163 cr | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.